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Introduction: Aberrant turnover of the actin cytoskeleton is intimately associated with cancer cell migration and
invasion. Frequently however, evidence is circumstantial, and a reliable assessment of the therapeutic significance
of a gene product is offset by lack of inhibitors that target biologic properties of a protein, as most conventional
drugs do, instead of the corresponding gene. Proteomic studies have demonstrated overexpression of CapG, a
constituent of the actin cytoskeleton, in breast cancer. Indirect evidence suggests that CapG is involved in tumor
cell dissemination and metastasis. In this study, we used llama-derived CapG single-domain antibodies or
nanobodies in a breast cancer metastasis model to address whether inhibition of CapG activity holds
therapeutic merit.
Methods: We raised single-domain antibodies (nanobodies) against human CapG and used these as intrabodies
(immunomodulation) after lentiviral transduction of breast cancer cells. Functional characterization of nanobodies
was performed to identify which biochemical properties of CapG are perturbed. Orthotopic and tail vein in vivo
models of metastasis in nude mice were used to assess cancer cell spreading.
Results: With G-actin and F-actin binding assays, we identified a CapG nanobody that binds with nanomolar affinity
to the first CapG domain. Consequently, CapG interaction with actin monomers or actin filaments is blocked.
Intracellular delocalization experiments demonstrated that the nanobody interacts with CapG in the cytoplasmic
environment. Expression of the nanobody in breast cancer cells restrained cell migration and Matrigel invasion.
Notably, the nanobody prevented formation of lung metastatic lesions in orthotopic xenograft and tail-vein models
of metastasis in immunodeficient mice. We showed that CapG nanobodies can be delivered into cancer cells by
using bacteria harboring a type III protein secretion system (T3SS).
Conclusions: CapG inhibition strongly reduces breast cancer metastasis. A nanobody-based approach offers a fast
track for gauging the therapeutic merit of drug targets. Mapping of the nanobody-CapG interface may provide a
platform for rational design of pharmacologic compounds.* Correspondence: jan.gettemans@ugent.be
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Aberrant turnover of the actin cytoskeleton is intimately
associated with cancer cell migration and invasion. A
large number of actin-associated proteins act as down-
stream executioners of signals integrated by a.o. small
GTPases of the Rho family [1]. Causal relations have
been established between perturbed expression, subcel-
lular localization or activity of many actin-associated
proteins, and cancer cell invasion. Hence, as in many
other research areas, actin-regulating proteins are being
proposed as new potential targets for drug development
at a swift pace. Such targets include factors that promote
actin polymerization, such as Arp2/3 and formin [2] or
the actin-bundling proteins fascin, filamin-A, and Mena
[3], to mention only a few. Alternatively, proteins resid-
ing in structures like invadopodia (N-WASp, cortactin)
[4], or filopodia (Ena/VASP proteins) [5] are considered
to be possible targets of interest. These structures con-
tribute to cell-membrane protrusion and/or enhanced
focal metalloprotease activity, leading to local degrad-
ation of the extracellular matrix, with ensuing invasion
of the surrounding tissue. Thus, cytoskeletal compo-
nents may constitute a plentiful source of potential
targets for further therapeutic development.
However, two important issues slow the progress in
this field: the apparent redundancy of the actin system
and the lack of tools to study this in a specific manner at
the protein level. The sheer number of actin-associated
proteins (>100) has led researchers to propose that some
functions of actin-associated proteins are redundant, and
this is supported by experimental studies. For instance, a
double knockout of CapG and gelsolin (two proteins with
actin filament-capping activity) shows only mild defects
[6], suggesting that the capping function is redundant
during development [7]. Other proteins like twinfilin,
Eps8, and CapZ, also display capping activity.
Notwithstanding these findings, it should be empha-
sized that an overwhelming lack of specific inhibitors
(targeting cytoskeletal constituents) allows scrutiny of
genetic data at the protein level.
CapG binds reversibly to the barbed end of actin
filaments (F-actin capping) in a calcium-dependent
manner [8]. Elevated CapG levels enhance cellular
motility/chemotaxis [9] and are associated with in-
creased invasion into collagen type I or chick heart
fragments [10]. Conversely, downregulation of CapG
expression reduces invasion of various cancer cell
lines [11-13]. In recent years, several proteomic stud-
ies demonstrated that CapG is overexpressed in vari-
ous types of cancer [14-16], including breast cancer.
Interestingly, higher expression of CapG was observed
in the tumor margin where invasive cells are located,
pointing to a role for CapG in tumor cell dissemin-
ation and metastasis [14].In this study, we used anti-CapG nanobodies as a tool
to question whether the actin-binding properties of
CapG are redundant at the protein level in a breast
cancer metastasis model. Nanobodies are the smallest
antigen-binding fragments from Camelid heavy-chain
antibodies [17]. They are easily cloned and can be used
as intrabodies. Importantly, they afford the opportunity
to block selected biologic functions of a resident target
antigen [18-20]. Our findings show that nanobody-based
protein-directed CapG inhibition (immunomodulation)
strongly reduces breast cancer metastasis, arguing against
CapG redundancy. In view of the difficulties associated
with developing small-compound inhibitors, we propose
that a nanobody-based approach offers a fast track
for gauging the role of distinct protein functions in
cell physiology.
Methods
MitoTracker Orange was purchased from Invitrogen
(Merelbeke, Belgium) and used according to the
manufacturer’s instructions. The pLV-CL vector was
kindly provided by Sven Eyckerman (VIB Dept. Medical
Protein Research, Ghent, Belgium). A polyclonal anti-
CapG antibody was used as described earlier [10].
Cloning
Nanobodies were generated as described [21]. In brief, a
llama was injected subcutaneously on days 0, 7, 14, 21,
28, and 35 with 500 μg human recombinant CapG per
injection. On day 39, anticoagulated blood was collected
for preparation of lymphocytes. Total RNA from periph-
eral blood lymphocytes was used as template for oligo
dT-primed first-strand cDNA synthesis. The VHH en-
coding sequences were amplified with PCR and cloned
into the PstI and NotI sites of the phagemid vector
pHEN4. A VHH library of about 107 independent trans-
formants was obtained. Three consecutive rounds of
panning were performed on solid-phase coated CapG
(10 μg/well). Enrichment for antigen-specific phages was
assessed after each round of panning. The enrichment
for antigen-specific phages was further evaluated by
polyclonal phage ELISA.
Nanobodies were cloned in the pcDNA3.1/V5-His6-
TOPO vector (Invitrogen) and its derivative (pMOM), in
pEGFP-N1, and in pHEN6c [19,20] with a V5-tag. A
nuclear export sequence (NES) from MAPKK or a
nuclear localization sequence (NLS) from SV40 was
additionally cloned in the BsrGI-site of pEGFP-N1. Plas-
mids pT3sCAPNb-Bla (TcR) were constructed by substitu-
tion of the GFPNb sequence in pT3sGFPNb-Bla [22].
Protein purification
Full-length wild-type human CapG and deletion fragments
were subcloned in the pGEX-5X-1 vector. Recombinant
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GST-fusion proteins. For purification of untagged CapG,
fusion proteins were cleaved with factor Xa. Purification of
recombinant V5-/His6-tagged nanobodies was performed
as described previously [20].
GST pull-down assay
Pull-down of CapG nanobodies with full-length or
truncated GST-CapG was performed as described pre-
viously [19].
Actin-binding assays
The actin monomer-binding assay was performed as
described earlier [20]. N-(1- pyrene)iodoacetamide
(pyrene)-actin (100 nM) (Cytoskeleton, Denver, CO,
USA) was incubated with CapG (100 nM) in the absence
or presence of recombinant CapG nanobodies (200 nM).
Fluorescence was measured at 388 nm after excitation at
365 nm. In the high-speed sedimentation assay, 6 μM actin
(Cytoskeleton) was incubated with CapG (7,2 μM) in the
absence or presence of CapG nanobodies (14.4 μM) in 1×
G-buffer [20]. After addition of polymerization buffer [19],
the reaction mixture was incubated for 30 minutes at room
temperature. Samples were centrifuged for 30 minutes at
100,000 g to sediment F-actin. Pellet and supernatant frac-
tions were separated by SDS-PAGE. Coomassie-stained
protein bands were scanned, and densities were quantified
with ImageJ. The actin-capping assay was performed
essentially as described earlier [23] by using 7-chloro-
4-nitrobenzeno-2-oxa-1,3-diazole (NBD)-labeled actin.
Fluorescence was measured at 535 nm after excitation
at 465 nm. Nanobodies were used at a concentration
of 500 nM.
Isothermal titration calorimetry
Binding of CapG to CapG nanobodies was measured at
30°C with ITC by using a Microcal VP-ITC, as described
earlier [20]. Untagged CapG and His6-tagged CapG
nanobodies were dialyzed against 20 mM Hepes, 150 mM
NaCl, pH 7.5, in the presence of 50 μM CaCl2 or 0.1 mM
EGTA.
Injection of nanobodies into MDA-MB-231 cells by
attenuated EPEC carrying T3SS
Growth of attenuated enteropathogenic E. coli (EPEC)
strains quad and ΔescN, infection of in vitro cultured
human cell line MDA-MB-231, and the β-lactamase
translocation assay were performed by following the
conditions described previously [22].
Stable cell lines
MDA-MB-231 cells stably expressing GFPNb- or GFP-
tagged CapG nanobodies were created according to the
manufacturer’s instructions (Lenti-XTet-On AdvancedInducible Expression System, Clontech, Saint-Germain-
en-Laye, France). Nanobodies were cloned in the pLVX-
Tight-Puro vector. For bioluminescent imaging, these
cells were additionally retrovirally infected with the
luciferase reporter (pLV-CL). Relative expression levels of
CAPNbs (GFP-tagged) and endogenous CapG were calcu-
lated by using purified recombinant CapG and GFP as
internal standards in immunoblot experiments.
Breast tumor metastasis in mice
All animal work was performed in compliance with the
guidelines of the ethical committee of the Faculty of
Veterinary Medicine (Ghent University, EC2012/028).
Llama immunization (Eurogentec, Seraing, Belgium) was
performed and monitored by an accredited veterinarian.
The animals were treated according to local guidelines for
animal care and handling. Female 3– to 4-weeks-old
immunodeficient NOD-SCID mice were used (Harlan
Laboratories, Indianapolis, IN, USA). Mice received doxy-
cycline (1 mg/ml) in 1% sucrose via their drinking water 4
days before injection of the cells and during the experi-
ment. MDA-MB-231 cells stably expressing GFP or GFP-
CAPNb2 and luciferase reporter were trypsinized and
washed with PBS. The breast cancer lung-metastasis model
was established by lateral tail vein injection of 1 × 106 cells
in 50 μl PBS. For the mammary fat pad tumor model, 2 ×
106 cells in 100 μl PBS containing 50% Matrigel were
injected into the mammary fat pads (MFPs) of mice. One
week before injection of cells in the MFPs, 3-weeks-old
mice were subcutaneously injected with 1 mg estradiol in
100 μl sesame oil (Sigma, Diegem, Belgium). Primary
tumor growth and development of metastases were moni-
tored weekly after i.p. injection of 150 mg/kg D-luciferin
by using an IVIS Lumina II System (Caliper Life Sciences,
Teralfene, Belgium). From the time tumors were palpable,
tumor length (L) and width (W) also were measured with a
caliper. Tumor volume was calculated as πLW2/6.
At day 56, lungs were retrieved from mice and fixed in
10% formalin solution (Sigma) overnight. Tissues were
embedded in paraffin, sectioned, stained with H/E,
and analyzed with microscopy (Leica M205 FA20
Stereomicroscope).
Immunoprecipitation, immunostaining, and microscopy
These assays were essentially performed as described
earlier [19].
Proteomics and mass spectrometry
See Additional file 1.
Cell-cycle experiments
MDA-MB-231 stable cell lines were induced with doxy-
cycline 48 hours before the experiment. Cells were
detached by using 3 mM EDTA in PBS. After
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fixed in 0.5% PFA for 1 hour at 4°C. Subsequently, cells
were permeabilized in 70% ethanol overnight at 4°C. Fi-
nally, cells were resuspended in PBS with propidium iod-
ide (40 μg/ml) and RNAse (100 μg/ml). Then 10,000 cells
were analyzed with a FACS Calibur Flow Cytometer (Cell-
Quest Pro software, BD Biosciences).
Oris cell migration and invasion assay
Plates were coated with collagen (rat tail, type I, BD,
50 μg/ml, migration) or basement membrane extract
(BME) solution (Matrigel; BD, 3.5 mg/ml, invasion)
before seeding of the cells. Cells were seeded at 40,000
cells/well (in medium with 1% FBS and 1 nM EGF),
except in the central well area, and allowed to attach for
3 hours. For migration experiments, images were acqui-
red, without mask (CellM, IX81 Olympus fluorescence
microscope). The area (μm2) covered by the cells was
measured at several time points (maximum 36 hours) for
the different replicates per condition. Migration efficiency
is based on the mean slope of linearly fitting the area-
over-time data (μm2/min). For the invasion assay, an
additional layer of BME was applied on top of the cells,
and fluorescence was measured with mask by using a FLX
800 microplate fluorescence reader (BIO-TEK instru-
ments, INC).
Statistical analysis
Data are expressed as means and standard deviation. For
migration/invasion experiments and imaging data of
mice, the SEM was used and analyzed with the Student t
test, or a nonparametric test (ANOVA on ranks) was
performed.
Results
CAPNb2 interaction with the first CapG domain inhibits
G-actin binding and F-actin capping
After immunization of a llama with human recombinant
CapG, several CapG nanobodies (CAPNb) were obtained
(see Materials and Methods). Because CapG regulates
cytoskeletal organization through Ca2+-dependent inter-
action with globular (G-) actin and filamentous (F-)
actin [8], we screened for nanobodies that perturb these
properties. For brevity, results are shown for selected
nanobody classes (based on the sequence of their third
complementarity-determining region (CDR3)). In Western
blot experiments, several nanobodies belonging to differ-
ent classes specifically recognized a ~40-kDa protein, cor-
responding to CapG, present in protein extracts obtained
from MDA-MB-231 breast cancer cells (see Additional
file 1: Figure S1). To investigate G-actin binding, we
performed a fluorescence-based assay using pyrene
(N-(1-pyrene)iodoacetamide)-labeled actin. The fluor-
escence intensity of pyrene-conjugated actin increaseson CapG binding [24] (Figure 1A). This increase in
fluorescence is modest because, unlike gelsolin, CapG
binds to only one actin monomer under nonpolymer-
izing conditions [24]. In the presence of CAPNb2 or
CAPNb3, the fluorescence decreased significantly, indi-
cating that these nanobodies (partially) prevent CapG
interaction with G-actin. CAPNb4, 5, and 6 showed no
significant effect.
We next performed F-actin sedimentation assays by
incubating actin with an equimolar concentration of
CapG under conditions that favor actin polymerization
(Figure 1B,C). Actin filaments and monomeric actin
were separated with high-speed centrifugation, and the
resulting pellets and supernatants were analyzed with
SDS-PAGE and quantified. The extent of polymerization
(that is, actin in pellet) is reduced as a result of G-actin
scavenging by CapG (Figure 1B,C, lane 4), unless a
nanobody blocks CapG-actin interaction. After incuba-
tion with CAPNb4, the bulk of actin was found in the
supernatant with a smaller F-actin fraction in the pellet,
suggesting that CAPNb4 has no effect on actin binding by
CapG (Figure 1C, lane 7). However, we noticed a reversal
in the G-/F-actin distribution on addition of CAPNb2.
More actin was recovered in the pellet (Figure 1C, lane 5).
Quantification of these experiments (Figure 1D) de-
monstrates that only CAPNb2 significantly inhibits actin
monomer binding by CapG.
We then determined whether nanobodies inhibited
F-actin capping by CapG. The fluorescence of short
unlabeled F-actin nuclei increased when 7-chloro-4-
nitrobenzeno-2-oxa-1,3-diazole (NBD)-labeled actin mono-
mers were added, but this was inhibited by CapG
(Figure 1E). The filaments remained capped in the
presence of all nanobodies that were tested, except
for CAPNb2. CAPNb2 blocked capping, as evidenced
by the reappearance of polymerization kinetics similar
to the conditions in which NBD-actin was polymer-
ized alone (Figure 1E). Thus, from the set studied,
CAPNb2 was the only nanobody inhibiting the associ-
ation of CapG with both G-actin and F-actin. For this
reason, we selected this nanobody for further detailed
analysis, by using other CAPNbs as controls.
Calorimetry experiments (thermodynamic parameters
are summarized in Additional file 1: Table S1) revealed
that the Kd of CAPNbs for CapG ranged from 150 nM to
0.8 nM in the presence of calcium. Interaction is mostly
enthalpy driven (Additional file 1: Figure S2). CAPNb2
(Kd = 23 nM and 4 (Kd = 5.3 nM) interact with CapG in a
Ca2+-dependent manner (Additional file 1: Table S1), un-
like CAPNb7 which binds to CapG irrespective of calcium,
suggesting an interaction with different epitopes.
To address this further, we used glutathione-S-transferase
(GST) pull-down experiments. CapG is a member of
the gelsolin family of actin-associated proteins. This
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Figure 1 CAPNb2 blocks CapG interaction with monomeric actin and actin filaments. (A) G-actin-binding assay. CAPNb2 and 3 counteract
a CapG-triggered increase in pyrene-labeled actin fluorescence. Intrinsic fluorescence of pyrene-actin was normalized to 1. A, actin; C, CapG; RFUs,
relative fluorescence units. (B) Principle of the actin sedimentation assay. Actin monomers freely polymerize in the absence of CapG (1). CapG
sequesters actin monomers, preventing their incorporation into filaments (2). If a nanobody prevents interaction between CapG and actin
monomers, the sequestration effect is lost, and actin will polymerize (3). A nanobody may interact with CapG without affecting the sequestration
of actin monomers, resulting in decreased polymerization (4). (C) CAPNb2 reduces the ability of CapG to sequester actin monomers in a
sedimentation assay. Supernatants (SNs) and actin pellets (Ps) were fractionated with high-speed centrifugation. Proteins were separated with
SDS-PAGE and visualized with Coomassie staining. Lanes 1, 2: controls. BSA does not affect actin polymerization. DNaseI (nanomolar affinity for
G-actin) strongly blocks actin polymerization. Lanes 3/, –4: CapG reduces actin sedimentation. Actin level in the pellet is reduced while actin in
the SN is increased. Lane 5: CAPNb2 counteracts the effect of CapG by increasing the actin fraction in the pellet and decreasing actin in the SN.
Lanes 6 through 9: Other nanobodies have no significant effect. (D) Quantification of the experiment in (C). A, actin; C, CapG. (E) F-actin-capping
assay. Capping of F-actin seeds by CapG prevents the initial increase in fluorescence in the control condition and an increase in final F-actin level.
The initial increase is due to high elongation rates of added F-actin seeds. CAPNb2 prevents CapG-dependent F-actin capping and results in actin
polymerization kinetics comparable to the control. Student t test was performed: *P < 0.05; **P < 0.005; n = 3.
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structural repeats of ~120 amino acids. Full-length CapG
and truncation mutants were used, consisting of a single
gelsolin-like repeat (S1, S2, or S3) or a combination of
two repeats (Figure 2A,B, top panel). As shown in
Figure 2B, all nanobodies were retained by full-length
CapG (lane 2) but did not react to a significant degree
with GST alone (Figure 2B, lane 1). Although some
deletion fragments of CapG were subject to partial
degradation, we observed that CAPNb4 binds strongly
to GST-S1 and GST-S1-S2, suggesting that its epitope is
located in the S1 domain. The same applies to CAPNb2
and 3, although their interaction was overall weaker
compared with CAPNb4 or below the detection limit
(CAPNb3 and GST-S1-S2). This may be caused by the
bulky GST moiety, which is twice the size of a nano-
body, and GST could interfere with nanobody binding
to CapG (note that ITC experiments were performed
with untagged CapG).
Alternatively, CapG deletion fragments may lack
part of an epitope. For instance, linker regions be-
tween the CapG domains may also constitute part of
the epitope recognized by nanobodies. Nanobodies 6
and 7 interact with GST-S2-S3 and GST-S2, indi-
cating that they, at minimum, bind to the second
CapG domain. Thus CAPNbs target different epitopes
in CapG.
We expressed EGFP-tagged nanobody cDNAs in
MDA-MB-231 breast cancer cells by lentiviral transduc-
tion to verify their ability to act as bona fide CapG
binders in the cytoplasmic environment (as intrabodies).
GFP-expressing or parental MDA-MB-231 cells were
used as negative control. CapG nanobodies were able to
co-immunoprecipitate CapG (Figure 2C; Additional file 1:
Figure S3A), indicating that they recognize endogenous
CapG. To substantiate this further, we performed delo-
calization experiments designed to alter intentionally the
subcellular distribution of endogenous CapG. CapG is
known to shuttle between the nucleus and cytoplasm
[25,26] and to distribute evenly between both com-
partments (Figure 2D, top panel). Tagging of CAPNb2
with the nuclear-localization sequence (NLS) of SV40
large T-antigen promoted enrichment of endogenous
CapG in the nuclear compartment (Figure 2D, middle
panel), and this effect was even more pronounced for
NLS-CAPNb4 (Figure 2D, lower panel). The apparent
weaker activity of CAPNb2 compared with CAPNb4
may be attributed to its lower affinity (Additional file 1:
Table S1) and the higher expression level of CAPNb4
(Figure 2C and Additional file 1: Figure S5A). Similar
findings were obtained with additional targeting strat-
egies (Additional file 1: Figure S3B-K). We therefore
conclude that nanobodies interact with CapG in the
cytoplasm as well as in distinct cell compartments.CAPNb2 induces multinucleation
To advance our understanding of the CAPNb2 mode of
action, we used quantitative proteomics involving SILAC
to label proteomes of MDA-MB-231 cells differentially
(Additional file 1: Figure S4A). By using LC-MS/MS ana-
lysis, we compared the CAPNb2 and CAPNb4 interac-
tomes (the complete protein list is shown in Additional
file 1: Figure S4C). We found that different tubulin
isoforms (tubulin beta chain and beta-4B chain) were
enriched in the CAPNb2 interactome (Additional file 1:
Figure S4B, Additional file 2 for complete list).
Although the biologic implications are not yet under-
stood, and further analysis is required, it was suggested
previously that CapG mediates cross-talk between the
actin cytoskeleton and microtubule-based organelles that
regulate cell division. CapG localizes at the mother
centriole in interphase, the mitotic spindle in mitosis,
and the midbody ring in abscission [27]. Furthermore,
genome-wide transcript profiling of the cell cycle also
revealed upregulation of CapG in G2, before the onset of
mitosis [28].
As these data suggest that CAPNb2 might affect cell
division, we analyzed MDA-MB-231-CAPNb cells with
flow cytometry. Results showed that CAPNb2 gives rise
to a significant increase in G2/M cells (compared to
GFP control cells) as well as to a third cell subpopula-
tion (Figure 3B,D), indicative of multinucleated cells,
compared with MDA-MB-231 cells expressing either
GFP (Figure 3A,D) or CAPNb4 (Figure 3C,D). These
changes occur primarily at the expense of cells in S-
phase and, to a minor extent, a reduction in the G0/G1
population.
CAPNb2 restricts migration, Matrigel invasion, and
metastasis of MDA-MB-231 breast cancer cells
To ascertain whether CAPNb2 reduces the migratory
and invasive properties of cells in vitro, we used ORIS
migration and invasion assays [29]. We used MDA-MB-
231 cells with doxycycline-inducible expression of GFP-
tagged nanobodies (Additional file 1: Figure S5A). By
using recombinant CapG and GFP as internal standards,
we calculated that CAPNb2 is expressed at a concentra-
tion equivalent to endogenous CapG (Additional file 1:
Figure S5B). CAPNb4 expression is 4.4-fold higher
(Additional file 1: Figure S5A). As depicted in Figure 4A,
CAPNb2-EGFP expressing MDA-MB-231 cells showed
markedly reduced migration capabilities on a 2D collagen
coating, as compared with control (GFP) or CAPNb4-
EGFP-expressing cells. Changing the growth conditions
from 10% FBS to 1% FBS/1 nM EGF demonstrated that
the three cell lines had comparable S-phase popula-
tions, indicating that proliferation effects can be excluded
(Additional file 1: Figure S5C). Next, Matrigel invasion
was investigated by using the ORIS invasion system.
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Figure 2 Epitope mapping and nanobody functionality as intrabody. (A) Schematic representation of GST-fusion proteins used in pull-down
experiments. (B) Epitope mapping. Glutathione-S-transferase pull-down assays with recombinant CAPNbs (left, input) and GST-CapG fragments
(indicated on top) were evaluated with SDS-PAGE and coomassie staining. (C) Co-immunoprecipitation. EGFP-tagged CAPNbs or a GFP control
(numbers indicated on top) were stably expressed in MDA-MB-231 cells and detected in cell extracts (top panel). They were retrieved from cell
extracts with a polyclonal anti-EGFP antibody (bottom panel). All CAPNbs immunoprecipitated endogenous CapG (middle panel). CE, crude
extract. (D) Upper panels: MDA-MB-231 cells were transfected with EGFP (control) and stained for endogenous CapG (red) and show the typical
nucleocytoplasmic distribution of CapG. Middle panels: MDA-MB-231 cells were transfected with CAPNb2-EGFP coupled to the SV40 large
T-antigen nuclear-localization sequence (NLS), promoting a stronger CapG enrichment in the nucleus. Lower panels: MDA-MB-231 cells were
transfected with CAPNb4-EGFP coupled to the SV40 large T-antigen NLS, redirecting endogenous CapG (red) nearly completely to the nucleus.
DAPI staining of the nucleus is shown in blue at right. Bar, 10 μm. Quantification of this experiment is shown in the histogram at right. The
nuclear enrichment of CapG was evaluated by determining the ratio of cytoplasmic versus nuclear CapG. Statistics were performed on 50 cells
per condition, with the EGFP (control) condition as reference (***P < 0.001).
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Figure 4 CAPNb2 restrains lung metastasis of breast cancer cells. (A) In vitro cell migration. CAPNb2 significantly reduces migration of MDA-
MB 231 cells; n = 6 (CAPNb2), 7 (CAPNb4) and 7 (GFP), P = 0.017 CAPNb2 versus GFP. Ns, not significant. (B) Matrigel invasion. MDA-MB-231 cells
stably expressing CAPNb2 are not invasive compared with GFP-transduced cells (t test, P = 0.046; n = 3). RFU, relative fluorescence unit. (C, D)
MDA-MB-231-CAPNb2-EGFP cells display fewer broad lamellipodia (t test, P = 0.00013; n = 3). (E) Orthotopic metastasis model. Noninvasive bio-
luminescence images of mice injected with GFP control cells or CAPNb2 cells. A red line (55d) marks the region of interest. H/E stainings of lung
sections are at right. Arrows, macrometastases. (F) Normalized photon-flux profile from lungs at the indicated times in the orthotopic metastasis
model. t38 P = 0.0240; t55 P = 0.0339; n = 6 to 7. (G) Tail-vein metastasis model. Bioluminescence images of mice injected with GFP control cells or
CAPNb2 cells. A red line (55d) marks the region of interest. H/E stainings of lung sections are at right. Arrows, macrometastases. (H) Normalized
photon-flux profile from lungs at the indicated times in the tail-vein metastasis model. t18 P = 0.0204; t38 P = 0.0092; t55 P = 0.0104; n = 7. A mouse
in the GFP cohort (n = 4) with an unusually high normalized photon flux of 2.93 × 107 photons/s was excluded. The total photons/s was measured
in a standard-sized circular region of interest encompassing the murine chest. For normalization, we set to 1 the average photon flux
at day 0 of the lungs of mice injected with CAPNb2-GFP cells. Error bars represent mean ± SEM except for D, in which mean ± SD are
shown. *P < 0.05; ***P < 0.001.
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the Matrigel, whereas CAPNb4 triggered only a
partial reduction in invasion of MDA-MB-231 cells
(Figure 4B). Microscopic analysis showed a less-polarized
morphology of CAPNb2-expressing cells with fewer broad
lamellipodia (containing membrane ruffles), as com-
pared with CAPNb4 or GFP-MDA-MB-231 control cells
(Figure 4C,D).
We next determined whether CAPNb2 could prevent
metastasis of breast cancer cells in mice. MDA-MB-231-
CAPNb2-GFP and MDA-MB-231-GFP (control) cells
were transduced with a luciferase reporter (Additional
file 1: Figure S5D) and injected into the mammary fat
pads or into the tail vein of immunodeficient (NOD-
SCID) mice. Subsequently, the occurrence of lung
metastases was monitored with noninvasive biolumi-
nescence imaging. CAPNb2 markedly restrained the
occurrence of lung metastases in both the orthotopic
(Figure 4E,F) and tail-vein (Figure 4G-H) models (>90%
reduction in photon flux). Postmortem examination of
the animals confirmed that bioluminescence in the lungs
originated from metastasized cells (data not shown).
Hematoxylin and eosin staining of lung sections revealed
many macrometastases in animals injected with GFP
control cells (Figure 4E,G right, upper panels). Ki-67
immunostaining indicated highly proliferative potential of
GFP cells (Figure 5A,C) and macrometastatic colonies
stained positive for human vimentin (Figure 5E,G). In
contrast, mice injected with MDA-MB-231-CAPNb2 cells
showed no macrometastases in the lungs; few microme-
tastatic lesions were observed at higher magnification
(Figure 5B,D,F,H). Hematoxylin and eosin staining of lung
metastatic lesions in tail vein and orthotopic models, as
well as Ki-67/vimentin staining of primary tumor sections,
are shown in Additional file 1: Figure S6 and S7, respect-
ively. Interestingly, data suggest that CAPNb2 also af-
fected primary tumor growth and local invasion into the
vascular layers of the abdominal wall. The average tumor
volume after 8 weeks was approximately 3 times smallerthan the tumor volume of mice injected with control cells
(Additional file 1: Figure S5E).
Injection of CAPNbs into MDA-MB-231 cells by the type III
protein-secretion system (T3SS) of E. coli
Unmodified nanobodies do not spontaneously cross the
plasma membrane (our unpublished data), a constraint
limiting their therapeutic potential when targeting intra-
cellular proteins. Some enteropathogenic E. coli (EPEC)
use a type III protein-secretion system (T3SS) to inject
effector proteins into cells [30-32]. The T3SS of EPEC
strains was shown to inject a GFP-specific nanobody
(GFPNb) into the cytoplasm of HeLa cells [22]. As with
GFPNb, we tagged CapG nanobodies with the N-
terminal T3s signal sequence of the E. coli-secreted pro-
tein F (EspF) effector and the β-lactamase (Bla) reporter
(Figure 6A) [22,33]. Plasmids were transformed into an
attenuated EPEC strain assembling a functional T3SS,
named quad [22]. This strain is a quadruple mutant of
EPEC wild-type strain E2348/69 [34] that lacks the adhe-
sin Intimin and three major effectors (Tir, EspF, and
Map) [35,36]. Plasmids were also transformed into an
EPEC E2348/69 ΔescN mutant lacking the essential
ATPase of the T3SS [22,36]. MDA-MB-231 cells were
infected with these bacteria and incubated with the Bla
substrate CCF2. Hydrolysis of CCF2 by translocated nano-
bodies fused to Bla caused a shift in its fluorescence emis-
sion from 520 nm (green) to 450 nm (blue) (Figure 6A,B).
Microscopic analysis demonstrated that GFPNb, CAPNb2
and 4 are injected into the cytoplasm of MDA-MB-231
cells by the attenuated EPEC quad bacteria (Figure 6B, left
panels). In contrast, green fluorescence was observed in
MDA-MB-231 cells infected with ΔescN strain (Figure 6B,
right panels). The fluorescence of infected MDA-MB-
231 cells was quantified in three independent infection
experiments, showing a clear increase in the blue/green
450/520-nm fluorescence ratio with EPEC quad bacteria
carrying T3s-Bla fusions of GFP or CapG nanobodies
(Figure 6C). Therefore, attenuated EPEC bacteria with a
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Figure 5 Ki-67 and vimentin staining of lung metastatic lesions. (A-D) Ki-67 staining of histologic sections. Representative images showing
proliferating cells in lung sections obtained from animals injected with MDA-MB-231-GFP cells (A,C) or MDA-MB-231-CAPNb2 cells (B,D).
Erythrocyte peroxidase activity contributes to the weak staining in (A,D). (E-H) Vimentin staining. Representative images showing vimentin-positive
MDA-MB-231 cells in lung sections obtained from mice injected with MDA-MB-231-GFP cells (E,G) or MDA-MB-231-CAPNb2 cells (F,H).
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MDA-MB-231 cells.
Discussion
Our genome encodes several proteins with actin
filament-capping activity [7,37]. On the basis of this
multiplicity, it has been proposed that similar proteinsperform overlapping functions. Consequently, inactivation
or genetic ablation of one capping protein is not expected
to trigger major defects in cell physiology because similar
proteins can perform the same task. CapG-knockout mice
are viable, fertile, and show no gross pathologic defects,
suggesting that CapG is redundant at the genetic level
during development [6]. However, the findings reported
A B
C
Figure 6 T3SS-mediated injection of CapG nanobodies in MDA-MB-231 cells. (A) Schematic depicting injection of a VHH (nanobody) fused
to a T3-secretion signal (T3s) and β-lactamase (Bla) reporter into a mammalian cell by the T3SS of enteropathogenic E. coli (EPEC) strains. The
nonfluorescent Bla substrate (CCF2/AM) is transformed by cellular esterases to the green fluorescent substrate CCF2. CCF2 hydrolysis by Bla results
in blue fluorescence. (B) Blue fluorescence is observed on infection with attenuated EPEC bacteria (quad) carrying T3s-Bla fusions of GFPNb
(positive control), CAPNb2 and CAPNb4. Green fluorescence is observed in MDA-MB-231 cells infected with ΔescN strains (lacking the essential
ATPase of the T3SS) or a Bla construct lacking the T3s signal sequence (pCX340). (C) Quantification of the fluorescence intensity ratio 447/520 nm
of cultures of MDA-MB-231 cells infected with attenuated EPEC quad strains, or EscN-deficient strains, carrying pCX340 (negative control) and
T3s-Bla fusions of GFPNb, CAPNb2, and CAPNb4. Results are expressed as mean ± SEM of three independent infection experiments for every
bacterial strain. Data were analyzed by using one-way analysis of variance (ANOVA) and Bonferroni Multiple Comparison Test with the PRISM
software (Graphpad) to calculate the P values of each data set with the control (quad pCX340). Asterisks (***) indicate P < 0.001.
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protein level or under pathologic conditions, because
CAPNb2 reduced metastatic spread by >95% in orthotopic
and tail-vein models of metastasis by preventing CapG
from binding to actin filaments and regulating their
polymerization status. Surprisingly, we did not ob-
serve gross changes in the organization of the actin
cytoskeleton in MDA-MB-231 cells that express CAPNb2.
However, similar findings were reported previously in cells
that overexpress CapG [9]. Although MDA-MB-231 cells
are known to express substantial amounts of other
capping proteins, such as twinfilin and gelsolin, these
polypeptides cannot act as a CapG proxy. As such, thesefindings point to an important role for CapG-dependent
regulation of actin-filament turnover during metas-
tasis, and this is supported by several independent
proteomic studies [12,14-16,38]. Hypoxic conditions
probably contribute to CapG-dependent enhanced me-
tastasis. Several functional HIF-1α-responsive elements
have been identified by reporter assays and chromatin
immunoprecipitation in the region upstream of the
CAPG gene. Furthermore, HIF-1α or hypoxic condi-
tions enhance CapG expression in leukemic U937T
cells [39].
Based on our results, we speculate that many other
structural proteins may be endowed with a higher
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quently, however, specific and high-affinity inhibitors
targeting such proteins are wanting, because of their
non-enzymatic character. Macroketones that target
the actin-bundling protein fascin [40] or the Arp2/3
inhibitors CK-0944636 and CK-0993548 [41] are an
exception in this regard. Unlike these small com-
pounds, however, expression of an intrabody can be
tuned in an inducible manner and adjusted to the ex-
pression level of the target antigen, thereby minimiz-
ing off-target effects.
In addition, when applied to multidomain or multifunc-
tional proteins, nanobodies may provide more possibilities
for selective functional inhibition. Nanobodies may thus
progress into a powerful instrument to help explain the
myriad phenomena that are based on the cellular actin
system, and which require new tools and models [42].
Whether CapG represents a bona fide therapeutic target
in relation to metastasis requires further investigation as
well as expansion of currently available technologies.
Nevertheless, we argue that nanobodies in general
appropriately mimic the activity of pharmacologic com-
pounds by directly targeting a protein (function) of inter-
est. Through detailed mapping of a therapeutic epitope,
(that is, by x-ray crystallography [43]), nanobodies can be
valuable as a stepping stone toward rational design of
organic compounds that bind to such an epitope. Further
elaboration of the nanobody-injection approach with non-
pathogenic E. coli bacteria endowed with a functional
T3SS will make a whole new repertoire of putative targets
more accessible, many of which play a role in the etiology
or progression of various diseases, including, but not
limited to, cancer.
In this regard, it is interesting to note the capacity
of commensal and probiotic E. coli to selectively pro-
liferate in solid tumors, including breast tumors, after
systemic administration [44,45] and that certain pro-
biotic E. coli strains are currently used in human
therapy [46,47].
Conclusions
Perturbing the interaction between CapG and actin
strongly reduces breast cancer metastasis in immuno-
deficient mice. Gene products that are redundant at
the genetic level may yet represent valid drug targets.
It is to be expected that protein-level inhibition of
other cytoplasmic structural (nonenzymatic) polypep-
tides in this manner will contribute to quick assess-
ment of their role in cancer cell behavior. Given their
ease of production, in addition to high specificity/af-
finity and stability in vitro and in vivo, we argue that
nanobodies represent a preferred instrument to trig-
ger protein functional knockouts, thereby adequately
simulating drug activity.Additional files
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